KD-CAAP (Kawasaki Disease Coronary Artery Aneurysm Prevention) trial: first site activated and ready for recruitment

KD-CAAP is the first investigator driven trial funded by conect4children to have a site activated and to start the patients’ recruitment. KD-CAAP main objective is to  determine whether adding immediate corticosteroid treatment to standard of care (intravenous immunoglobulin (IVIG) and aspirin) will reduce coronary artery aneurysm (CAA) rates in Kawasaki Disease patients.
Find more about this trial here: https://conect4children.org/studies-kdcapp/
Read the full press release here: https://conect4children.org/news/pr_kdcaapp_09_2020/
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777389. The Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA